Tang Capital Management LLC

Kevin Tang (10% Owner) acquired 57,210 shares at BOLD over 3 days for $141,864.66; now holds 2,698,518 shares.

Kevin Tang, a 10% owner, executed 3 separate purchases totaling 57,210 shares for $141,864.66 between July 6–8, 2026, at an average price of $2.48, increasing his stake by 2.2%. The current stock price of $2.45 sits 12.2% below the 52-week high of $2.79, yet the stock has risen 71.3% over the prior 30 days and 114.9% over 90 days. Notably, Tang's same-ticker history at BOLD shows 5 prior buys within the preceding 5 days (June 29–July 2), all of which remain too recent to measure 30- or 90-day outcomes. The company reported a full-year net income of $-13,555,000.00 and carries a market cap of $55,037,071.95, reflecting ongoing unprofitability. This pattern of sustained accumulation during a period of sharp share price appreciation in an unprofitable company warrants scrutiny into whether the buying reflects conviction or responds to near-term price momentum.

Kevin Tang (10% owner) purchased 107,463 shares for $268,880.37 across 4 transactions June 30–July 2 at $2.49–$2.54, raising stake to 2.64M shares; company unprofitable with -$13.6M net income

Kevin Tang, a 10% owner at Boundless Bio, executed 4 separate purchases totaling 107,463 shares for $268,880.37 between June 30 and July 2, 2026, at prices ranging from $2.49 to $2.54 (blended average $2.50). This increased his holdings by 4.2% to 2.64M shares. The purchase occurred at a notably reduced valuation: the current price of $2.50 is 10.4% below the 52-week high of $2.79, though the stock has surged +74.8% over 30 days and +131.5% over 90 days from earlier lows. The company remains unprofitable with net income of -$13.6M over its most recent full fiscal year, a fundamental backdrop that contextualizes the accumulation. Tang's cross-ticker track record shows 20 prior open-market buys with modest average returns (30d: +3.0%, 90d: +3.1%), suggesting measured execution rather than predictive accuracy. The multi-transaction structure and modest blended price relative to recent market action warrant examination of both the timing of this accumulation and the company's path to profitability.

Kevin Tang (10% Owner) bought 286,333 shares at BOLD for $714,768.12 across 6 transactions; holdings rise to 2,533,845 shares (+12.7%).

Kevin Tang, a 10% owner, executed 6 separate purchases totaling 286,333 shares for $714,768.12 over four trading days (June 25–29, 2026) at prices ranging from $2.47 to $2.56, with a blended average of $2.50. The transaction increased his stake by 12.7% to 2,533,845 shares. The purchases occurred while the stock was trading at $2.45 (current price), down 12.2% from its 52-week high of $2.79 but up 69.0% over the prior 30 days and up 122.7% over the prior 90 days. Boundless Bio is unprofitable, with net income of $-13,555,000.00 and a market cap of $55,037,071.95. Across all prior open-market trades, Tang's cross-ticker track record shows 20 buys with average 90-day returns of +3.1%, though his win rate stands at 50.00%.

CEO Kevin Tang purchases 814,606 shares totaling $12,455,227.01 across 5 transactions at $15.28–$15.35

Kevin Tang, CEO of Aurinia Pharmaceuticals, made 5 separate open-market purchases totaling 814,606 shares for $12,455,227.01 between May 29 and June 2, 2026, at a blended average price of $15.29, raising his holdings from 12,229,500 to 13,044,106 shares. This represents a 6.7% increase in his pre-transaction position at a company with strong fundamentals: $77,705,000 in latest quarterly revenue, $34,355,000 net income, 20.4% annual revenue growth, and a P/E of 6.63. His prior 5 purchases at AUPH were all well-timed at the 90-day mark, establishing a consistent pattern of buy timing at this ticker. The current stock price of $15.39 reflects minimal movement from the purchase window, positioning this filing for near-term market assessment against his demonstrated buying pattern.